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Abstract
Background: Chlamydiae are obligate intracellular pathogens that possess a type III secretion
system to deliver proteins into the host cell during infection. Small molecule inhibitors of type III
secretion in Yersinia, termed INPs (Innate Pharmaceuticals AB) were reported to strongly inhibit
Chlamydia growth in epithelial cells. In this study we have analyzed the effect of these drugs on
bacterial invasiveness.
Results: We demonstrate that INPs affect Chlamydia growth in a dose dependent manner after
bacterial invasion. The efficiency of C. trachomatis L2 and C. caviae GPIC entry into host cells was
not altered in the presence of INPs. In C. caviae, entry appears to proceed normally with
recruitment of actin and the small GTPases Rac, Cdc42 and Arf6 to the site of bacterial entry.
Conclusion:  INPs have a strong inhibitory effect on Chlamydia  growth. However, bacterial
invasion is not altered in the presence of these drugs. In the light of these results, we discuss several
hypotheses regarding the mode of action of INPs on type III secretion during the Chlamydia
infectious cycle.
Background
Chlamydiae  are obligate intracellular pathogens with a
complex developmental cycle. The first step is the attach-
ment of the infectious form, the elementary body (EB), to
a host cell. After entry, the bacteria differentiate into non-
infectious reticulate bodies (RBs), which reside inside the
host cell within a membrane-bound compartment,
termed the inclusion. In this protected niche, RBs replicate
and eventually differentiate into EBs, which, upon their
release from the host cell, can start a new round of infec-
tion.
Chlamydia, like many other gram-negative pathogens,
employ a type III secretion (T3S) system to deliver bacte-
rial proteins into the host cell [1]. A large family of
Chlamydia-specific proteins has been shown to be translo-
cated by this process by RBs into the chlamydial inclusion
membrane (Inc proteins) [2]. In addition, chlamydial
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effector proteins were also found to be secreted into the
host cell cytoplasm during intracellular replication [3].
The function of most of the T3S substrates remains to be
identified. Structural components of the type III secretion
machinery have also been detected on EBs [4-6] and it has
been shown that EBs possess functional secretion appara-
tuses [7].
Entry of Chlamydia into host cells requires the attachment
of EBs to the host cell surface. A number of surface associ-
ated molecules and receptors have been described, sug-
gesting that Chlamydia use multiple strategies for ensuring
adhesion to the host cell [8]. Upon entry, Chlamydia
induce actin rearrangements and small GTPases are
recruited to the bacterial entry site [9-12]. Interestingly,
the EB-associated T3S protein TARP (translocated actin
recruiting phosphoprotein) has actin nucleating activity
and is required for Chlamydia entry into host cells [13-16].
Other proteins might be translocated by T3S at the entry
step, which remain to be identified. Importantly, EBs are
metabolically inactive, and proteins that are translocated
during the entry process have been synthesized during the
previous infectious cycle and stored in the bacteria to be
translocated upon contact with the host cell.
Recently, we and others have shown that small molecule
inhibitors of the Yersinia type III secretion system, collec-
tively termed INPs, disrupt the progression of the cycle of
Chlamydia development [17-20]. In our previous study,
we reported a partial effect of INPs on bacterial invasion,
which was assessed by counting the number of inclusions
present at 40 h post infection (p.i.) in cultures that were
treated with drug for 3 h during infection. In order to clar-
ify if this observed effect is due to the inhibition of bacte-
rial invasion or to the inhibition of early events during the
onset of Chlamydia development, we further examined the
effect of INPs on Chlamydia entry.
Results
INPs affect Chlamydia development post entry
In our previous study, we used the small molecule
INP0400, a derivative of salicylidene acylhydrazide iden-
tified as a specific inhibitor of Y. pseudotuberculosis T3S. We
found that INP0400 progressively inhibited C. trachomatis
L2 replication in doses from 5 to 25 μM [17]. In the
present study we included another derivative of salicyli-
dene acylhydrazide, INP0341. Dose response studies on
chlamydial inclusion size showed that INP0341 was even
more potent than INP0400 in inhibiting C. trachomatis L2
replication, as 10 μM INP0341 was already sufficient to
strongly inhibit bacterial multiplication (Fig. 1A). We also
tested the effect of these two INPs on the development of
another strain of Chlamydia, C. caviae GPIC. At equivalent
concentrations of INPs, the effect on inclusion size was
always more pronounced on C. trachomatis than on C. cav-
iae inclusions, suggesting that the latter strain is less sus-
ceptible to the drug (Fig. 1A). Treatment with 60 μM
INP0341 resulted in a 99.8% reduction in the yield of
infectious C. caviae EB particles. This reduction in infectiv-
ity is much greater than the decrease in inclusion size. It is
consistent with the greater decrease in infectivity than
inclusion size that we saw previously with INP0400 on C.
trachomatis  L2 [17]. In subsequent experiments we
decided to use 60 μM of INPs, which fully inhibited devel-
opment of C. trachomatis L2, and had a very strong effect
on C. caviae multiplication.
In order to quantify the efficiency of Chlamydia entry in
the presence of INPs, HeLa cells were infected with C. tra-
chomatis L2 or C. caviae GPIC in the presence or absence
of INP0400 or INP0341. At 2.5 h p.i. extracellular and
intracellular bacteria in mock-treated (DMSO) or 60 μM
INP-treated cultures were measured as previously
described [11]. The efficiency of entry (intracellular/total
cell associated bacteria) was quantified. INPs had no sig-
nificant effect on C. trachomatis L2 and C. caviae GPIC
invasion, when present during infection (Fig. 1B). Identi-
cal observations were made when the cells and/or the bac-
teria were preincubated for 15 minutes in the presence of
INPs prior to infection or when bacteria were left to
adhere on the cells at 4°C before allowing internalization
to proceed at 37°C in the continuous presence of the drug
(data not shown).
Recruitment of actin and small GTPases to Chlamydia 
entry sites during infection in the presence of INPs
Although the overall efficiency of entry was not affected
by INPs over a 2.5 h period of infection, a possibility
remained that the bacteria used an alternative route of
entry in the presence of the drug. To rule out this possibil-
ity, we observed some of the molecular events that accom-
pany Chlamydia entry.
Upon contact with host cells, Chlamydia  activate small
GTPases and induce actin polymerization [8]. These
events are more pronounced in cells infected with C. cav-
iae GPIC [11] than in cells infected with C. trachomatis L2
[10]; therefore we used the former. To synchronize infec-
tion, bacteria were centrifuged onto the cells and fixed 10
minutes after contact. C. caviae GPIC entry sites showed
characteristic local actin rearrangements in control cells.
Similar actin aggregates were observed in cells treated with
INP0341 (Fig. 2A) or INP0400 (data not shown). The
number of actin aggregates per cell was identical in treated
and untreated samples (Fig. 2B).
The small GTPases Rac, Cdc42 and Arf6 are recruited to
the sites of C. caviae GPIC entry, and their activity is
needed for bacterial invasion [11,12]. HeLa cells were
transfected with either Rac-GFP, Cdc42-GFP or HA-tagged
Arf6 for 24 h before being infected with C. caviae GPIC. At
10 minutes p.i. cells were fixed and labelled for actin. RacBMC Microbiology 2009, 9:75 http://www.biomedcentral.com/1471-2180/9/75
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and Cdc42 were localized by the GFP signal; Arf6 was
labelled with anti-HA antibodies. Rac-GFP (Fig. 3A), Arf6
(Fig. 3B) and Cdc42-GFP (data not shown) were found to
be localized to the actin aggregates to the same extent in
cells infected in the presence of INPs as in control cells.
Therefore, INPs do not interfere with the recruitment of
small GTPases to C. caviae GPIC entry sites, which
strongly support the other observations that Chlamydia
entry proceeds normally in drug treated cells.
Discussion
Our data show that INPs do not inhibit the entry of
Chlamydia into host cells. The efficiency of bacterial inva-
sion has been investigated with two Chlamydia species, C.
Effect of INPs on Chlamydia intracellular development and entry Figure 1
Effect of INPs on Chlamydia intracellular development and entry. (A) HeLa cells infected with C. trachomatis L2 (top) 
or C. caviae GPIC (bottom) were grown in the presence of INP0341 for 24 h at the concentrations indicated. After fixation, 
bacteria were labelled with anti-EfTu antibody (green) and host cell nuclei were stained with Hoechst 33342 (blue). (B) HeLa 
cells were infected with C. trachomatis L2 or C. caviae GPIC for 2.5 h in the presence or absence of 60 μM INP0400 or INP0341 
and extracellular and intracellular bacteria were differentially immunolabelled as previously described [11]. The number of 
extra- and intracellular bacteria in untreated and treated cells were counted in 15 fields with an average of 75 bacteria per field. 
The efficiency of entry is expressed as the ratio of intracellular to total cell-associated bacteria (intracellular and extracellular). 
The data shown represent the average and the standard error of 30 fields from two independent experiments.BMC Microbiology 2009, 9:75 http://www.biomedcentral.com/1471-2180/9/75
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trachomatis L2 and C. caviae GPIC, and it was not modified
in the presence of the drug. The normal recruitment of
Rac, Cdc42 and Arf6 to C. caviae GPIC entry sites in the
presence of INPs further indicates that INPs do not inter-
fere with the mechanism of Chlamydia invasion.
Previously, we had reported a partial effect on Chlamydia
trachomatis L2 entry in the presence of INP0400 [17]. This
was based on the observation that treatment of the cells
with 40 μM INP0400, for the first 3 hours of infection,
resulted in a 40% reduction in the percentage of infected
cells, compared to non-treated cells. We interpreted these
data as a partial effect of the drug on bacterial entry. How-
ever, since we demonstrate here that Chlamydia invasion is
not impaired by treatment with INPs, a more likely expla-
nation is that other early events, following Chlamydia
entry, are required for the onset of infection and are sus-
ceptible to the drugs. Indeed, Chlamydia genes expressed
early in infection are needed to create a permissive envi-
ronment for successful bacterial replication [21]. In partic-
ular, some of the Inc proteins, which are T3S substrates,
are transcribed very early during infection and can be
detected in the inclusion as early as 2–4 h p.i. [7].
In support of our results, Wolf et al. and Slepenkin et al.
had reported that they were unable to inhibit C. trachom-
atis L2 entry in presence of INPs [18,19]. In the study of
Wolf et al. the effect of drug on the EB translocated protein
TARP, which probably plays a central role in the internal-
ization process of C. trachomatis was examined. Upon host
cell attachment, TARP is secreted in a type III dependent
manner by Chlamydia trachomatis and becomes rapidly
phosphorylated. Wolf et al., were unable to inhibit this
early tyrosine phosphorylation of TARP in cells treated
with another compound of the same family of INPs [18].
The lack of effect of INPs, which have been identified and
described as type III secretion inhibitors, on Chlamydia
entry is therefore surprising. Recent reports on the mode
of action of INPs which we would like to discuss here,
raise the question whether these drugs interfere with the
actual translocation process of T3S substrates or rather
inhibit at the level of transcription of T3S associated genes
or assembly of the T3S machinery.
Earlier studies suggested that INPs might affect the trans-
location of type III substrates per se, and indeed, in Yers-
inia, careful analyses suggest that it is the case [22]. So far,
the efficiency of INPs at blocking T3S in Chlamydia has
been shown only for substrates secreted by RBs, and their
target might be missing in EBs. In favour of this hypothe-
sis is the observation that Chlamydiae genomes encode
two homologues for the Yersinia lcrH chaperone for T3S
system structural components, lcrH-1 and lcrH-2 [23].
These genes are in clusters that are differentially expressed
during the developmental cycle. It was recently shown
that transcription of lcrH-1, which is expressed late in the
cycle, when EBs are forming, was inhibited by INP0341,
while transcription of lcrH-2, which is expressed earlier in
the cycle, was not [19]. Functional differences in the T3S
apparatuses of EBs and RBs might therefore explain a dif-
Recruitment of actin to C. caviae GPIC entry sites Figure 2
Recruitment of actin to C. caviae GPIC entry sites. HeLa cells were infected with FITC-labelled C. caviae GPIC in the 
presence or absence of 60 μM INP0341. At 10 minutes p.i. cells were fixed and actin filaments were visualized with Alexa-Fluor 
546-phalloidin. (A) Actin remodelling around FITC-labelled bacteria was observed in control cells as well as in cells treated 
with INP0341 (arrows). (B) Quantification of actin aggregates in the presence or absence of INP0341. The number of actin 
aggregates per field was divided by the number of cells in the field (n>30). The average and standard deviation from three fields 
are shown.BMC Microbiology 2009, 9:75 http://www.biomedcentral.com/1471-2180/9/75
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ference in sensitivity to the type III secretion inhibitors.
This would be consistent with our results and could
explain the lack of effect of INPs on Chlamydia entry.
As an alternative, it is possible that INPs have a different
mode of action on Chlamydia development than they have
on Yersinia, and do not block the translocation of effectors
per se. Importantly, the effect of INPs on chlamydial
development is fully reversed by the addition of iron [19],
while their inhibitory effect on Yersinia T3S is not (per-
sonal communication from Innate Pharmaceuticals AB).
In this case, INPs might affect one of two requirements for
effector protein secretion: (a) the assembly of functional
secretion apparatuses or (b) the synthesis of the substrates
recognized by the secretion machinery.
By acting on the formation of type III secretion appara-
tuses, INPs would only be effective when introduced
while the apparatuses are being made, i.e. in the intracel-
lular multiplication phase of Chlamydia development. In
support of this hypothesis, recent data strongly suggest
that, in the case of Shigella, INPs block assembly of the
type III secreton [24]. In Shigella, INPs were only effective
at inhibiting host cell invasion when added during
growth, rather than during the infection step.
If, on the other hand, INPs inhibited the synthesis of type
III secretion substrates, they would not affect entry either,
because the effectors needed for this step are not newly
synthesized during entry. INP0400 has been shown to
inhibit the secretion of IncA and IncG proteins, which are
produced during RB proliferation, and are rapidly translo-
cated upon synthesis, as they are only weakly detected in
RBs [25,26]. In contrast, Tarp and other potential T3S
effectors participating in the entry event are at least par-
tially stored in the RBs to be released by the EB form upon
infection. Recent data show that the expression of some of
the T3S genes (including genes coding for the secretion
apparatus) is down-regulated by INP0341 [19]. Similarly,
the Yersinia T3S system is down-regulated upon bacterial
exposure to INPs [22] and it has also been shown in Sal-
monella  that these compounds cause transcriptional
silencing of the Salmonella pathogenicity island 1 [27]. It
should be noted that if INPs act at a transcriptional level
Recruitment of Rac and Arf6 to C. caviae GPIC entry sites Figure 3
Recruitment of Rac and Arf6 to C. caviae GPIC entry sites. HeLa cells transfected with Rac-GFP (A) or Arf6-HA (B) 
for 24 h were infected with C. caviae GPIC in the presence of DMSO (control) or 60 μM INP0341. At 10 minutes p.i. cells were 
fixed and processed for immunofluorescence. Top panels show labelling for the small GTPases, middle panels show actin label-
ling and bottom panels show superimposition of the two images, as well as host cell nuclei stained with Hoechst 33342 (blue). 
Rac and Arf6 are recruited to sites of actin polymerization (arrows), both in control cells and in cells treated with INP0341.BMC Microbiology 2009, 9:75 http://www.biomedcentral.com/1471-2180/9/75
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in Chlamydia, they might not affect the secretion of all
effectors to the same extent. Therefore, at this stage INPs
should only be used cautiously to assess the mechanism
of secretion of a given chlamydial protein.
Down-regulation of transcription could perhaps also be
due to feedback inhibition resulting from blocking T3S
activity [24]. If, in Chlamydia, either the transcription of
T3S associated genes or the assembly of the T3S machin-
ery are inhibited, addition of the drugs at the end of one
cycle of infection is expected to affect the next round of
infection. This is exactly what was observed when looking
at the progeny of C. trachomatis infected cells treated with
INP0341 24 hours post infection [19]. In this experiment,
although the inclusions formed upon late INP0341 treat-
ment were as abundant as in control cells, there was a
decrease in the infectious progeny, suggesting that EBs
formed in the presence of INPs might be defective in their
ability to secrete type III effectors. However, due to the
asynchronicity of the Chlamydia developmental cycle, we
can not definitively rule out that the decrease in the for-
mation of infectious EBs when the drug is added late in
the cycle is not due to the now well documented reduc-
tion of RB multiplication upon INP treatment.
Conclusion
In the present study we demonstrate that small molecule
inhibitors of Yersinia T3S have a strong inhibitory effect
on Chlamydia growth but fail to inhibit Chlamydia inva-
sion. INPs had no significant effect on C. trachomatis L2
and C. caviae GPIC entry into epithelial cells. Moreover,
recruitment of actin and small GTPases to bacterial entry
sites was not altered. These results suggest that in the pres-
ence of INPs pivotal events in early Chlamydia biogenesis
following entry must be affected which could account for
the observed inhibition of Chlamydia growth. The inabil-
ity of INPs to interfere with the entry mechanism suggest
that the drug might not affect the translocation process
per se. We believe that the identification of the mode of
action of INPs on type III secretion in genetically tractable
bacteria will clarify this issue.
Methods
Cells, bacterial strains, antibodies and plasmids
HeLa cells were grown as described [11]. The Chlamydia
trachomatis L2 strain 434 (VR-902B) was from the ATCC
and the GPIC strain of C. caviae was obtained from Dr. R.
Rank (University of Arkansas). Plasmids coding for HA-
tagged Arf6, GFP-tagged Rac and GFP-tagged Cdc42 were
kindly given by Drs. Ph. Chavrier (Institut Curie, Paris), G.
Tran van Nhieu (Institut Pasteur, Paris) and E. Caron
(Imperial College, London), respectively. The mouse anti-
Chlamydia  antibody (unlabelled and FITC-conjugated)
was purchased from Argene, Biosoft. Alexa546-phalloi-
din, Alexa488-phalloidin, goat Alexa488-coupled anti-
mouse antibody and Hoechst 33342 were from Molecular
Probes. The mouse anti-EfTu antibody was a kind gift
from Dr. YX Zhang, Boston, USA. Rat anti-HA antibody
was from Roche and the TRITC-conjugated anti-rat anti-
body was from Jackson Immuno Research. Cy™-5-conju-
gated goat anti-mouse antibody was purchased from
Amersham.
INPs
Two salicylidene acylhydrazides, namely INP0400 and
INP0341, were provided by Innate Pharmaceuticals AB,
Umeå, Sweden. The compounds were dissolved in dime-
thyl sulfoxide (DMSO, Sigma) as 10 mM stock solutions
and used at the concentrations indicated.
Chlamydia entry assay
HeLa cells were infected with C. trachomatis L2 or C. caviae
GPIC in the presence or absence of 60 μM INP0400 or
INP0341 and centrifuged for 5 minutes at 770 g at room
temperature. Cells were fixed 2.5 h later and extracellular
and intracellular bacteria were labelled as described [11].
In brief, extracellular bacteria were labelled with anti-
Chlamydia antibody followed by anti-mouse Cy™-5 anti-
body. The cells were then permeabilized in PBS contain-
ing 0.05% saponin and 1 mg/ml BSA and intracellular
bacteria were labelled with FITC-conjugated anti-Chlamy-
dia antibody. The number of extracellular and intracellu-
lar bacteria was counted in 15 fields, with an average of 75
bacteria per field, in two independent experiments. The
efficiency of entry is expressed as the ratio of intracellular
to total cell-associated bacteria (intracellular and extracel-
lular).
Immunofluorescence microcopy
To visualize the effect of the drugs on Chlamydia develop-
ment, HeLa cells infected with C. trachomatis L2 or C. cav-
iae GPIC were grown in presence of INPs (or DMSO for
control) for 24 h, fixed, and labelled with anti-EfTu anti-
body followed by Alexa488-coupled goat anti-mouse
antibody. DNA was stained with 0.5 μg/ml Hoechst
33342 in the mounting medium.
Recruitment of actin to bacterial entry sites was visualized
with Alexa546-phalloidin in HeLa cells infected with
FITC-labelled C. caviae in the presence or absence of 60
μM INP0341 as described [11]. To visualize Arf6 and Rac
distribution, cells were transfected with HA-tagged Arf6 or
GFP-tagged Rac. Hela cells were infected with C. caviae
GPIC 24 h after transfection and spun for 5 minutes at
770 g at room temperature. At 10 minutes p.i. cells were
fixed and labelled with Alexa546-phalloidin (GFP-Rac
transfected cells) or Alexa488-phalloidin (Arf6-HA trans-
fected cells). Arf6 was labelled with a rat anti-HA antibody
(Roche, clone 3F10) followed by a TRITC-conjugated
anti-rat antibody (Jackson Immuno Research). Immun-Publish with BioMed Central    and   every 
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ofluorescence microcopy was performed with an epifluo-
rescence microscope (Axiophot, Zeiss, Germany) attached
to a cooled CDD camera (Photometrics, Tucson, AZ),
using a 63× Apochromat lens.
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